Altium Capital Management LP Buys Keros Therapeutics Inc, Celldex Therapeutics Inc, X4 Pharmaceuticals Inc, Sells Chardan Healthcare Acquisition 2 Corp, Palisade Bio Inc, Crinetics Pharmaceuticals Inc

• New Purchases: KROS, XFOR, AFMD, BCYC, ARCT, BBIO, RCOR, ICAD, TCON, DDI, FLUX, SRSA, VQS, SNDX, LAAA, GIW, CLAY, ONCR, LFMD, CMRX, HLMN, VRPX, SNAX, PRQR, ARYE, ALNA, MITA, ALGS, CLBR, SCYX, PSTX,
• Added Positions: CLDX, OCUL, NVRO, CTMX, CERS, IMTX, CDNA, VSTM, HAE, NTRA, LNTH, INSP, PTGX, MORF, XENE, SYRS, RNA, ILMN, ADMS, YMTX, ELOX, KRMD, GRTX, KDNY, ARQT, VREX, PROF, CSTL,
• Reduced Positions: CRNX, ISEE, PODD, XTNT, VRCA, GMED, TCRR, AUPH, KLR, CRDF, CTIC, TVTX, MYGN,
• Sold Out: CHAQ, PALI, EPIX, ECOR, SIEN, BCTX, IMVT, NSTG, GKOS, TBPH, XENT, STIM, INFI, AHAC, MCRB, LSAQ, RGNX, SRGA, SRSAU, FULC, CARA, RYTM, LAAAU, GIWWU, TARS, EYES, CVRX, CYTK, KRBP, AJAX, ARYD, SPNV, QELL, IRTC, COCP, INMB, VLON, HEPA, ONCT, MITAU, TKNO, CLBR.U, IFRX, ACEV, IKT, RCAT, SNCR, BTTR,

For the details of Altium Capital Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/altium+capital+management+lp/current-portfolio/portfolio

1. 1847 Goedeker Inc (GOEDWS) - 6,886,600 shares, 3.03% of the total portfolio.
2. BELLUS Health Inc (BLU) - 1,788,789 shares, 2.88% of the total portfolio.
3. Celldex Therapeutics Inc (CLDX) - 185,000 shares, 2.62% of the total portfolio. Shares added by 98.68%
4. CTI BioPharma Corp (CTIC) - 3,313,000 shares, 2.56% of the total portfolio. Shares reduced by 9.94%
5. Aldeyra Therapeutics Inc (ALDX) - 864,020 shares, 1.99% of the total portfolio.

Altium Capital Management LP initiated holding in Keros Therapeutics Inc. The purchase prices were between $29.27 and $43.71, with an estimated average price of $35.63. The stock is now traded at around $60.560000. The impact to a portfolio due to this purchase was 1.31%. The holding were 126,000 shares as of 2021-09-30.

Altium Capital Management LP initiated holding in X4 Pharmaceuticals Inc. The purchase prices were between $4.53 and $6.45, with an estimated average price of $5.49. The stock is now traded at around $4.800000. The impact to a portfolio due to this purchase was 1.12%. The holding were 804,598 shares as of 2021-09-30.

Altium Capital Management LP initiated holding in Affimed NV. The purchase prices were between $5.54 and $7.51, with an estimated average price of $6.59. The stock is now traded at around $6.730000. The impact to a portfolio due to this purchase was 1.08%. The holding were 665,000 shares as of 2021-09-30.

Altium Capital Management LP initiated holding in Bicycle Therapeutics PLC. The purchase prices were between $27.95 and $44.24, with an estimated average price of $35.01. The stock is now traded at around $60.860000. The impact to a portfolio due to this purchase was 1%. The holding were 92,000 shares as of 2021-09-30.

Altium Capital Management LP initiated holding in Arcturus Therapeutics Holdings Inc. The purchase prices were between $27.88 and $58.25, with an estimated average price of $44.8. The stock is now traded at around $36.650000. The impact to a portfolio due to this purchase was 1%. The holding were 80,000 shares as of 2021-09-30.

Altium Capital Management LP initiated holding in BridgeBio Pharma Inc. The purchase prices were between $46.87 and $64.24, with an estimated average price of $53.73. The stock is now traded at around $46.100000. The impact to a portfolio due to this purchase was 0.97%. The holding were 79,000 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in Celldex Therapeutics Inc by 98.68%. The purchase prices were between $28.95 and $55.99, with an estimated average price of $46.84. The stock is now traded at around $43.820000. The impact to a portfolio due to this purchase was 1.3%. The holding were 185,000 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in Ocular Therapeutix Inc by 117.06%. The purchase prices were between $9.7 and $14.34, with an estimated average price of $11.26. The stock is now traded at around $6.710000. The impact to a portfolio due to this purchase was 0.79%. The holding were 556,000 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in Nevro Corp by 89.59%. The purchase prices were between $101.99 and $166.36, with an estimated average price of $131.29. The stock is now traded at around $91.750000. The impact to a portfolio due to this purchase was 0.74%. The holding were 51,000 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in CytomX Therapeutics Inc by 43.04%. The purchase prices were between $4.32 and $6.43, with an estimated average price of $5.36. The stock is now traded at around $7.370000. The impact to a portfolio due to this purchase was 0.5%. The holding were 1,233,642 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in Cerus Corp by 35.08%. The purchase prices were between $4.79 and $6.68, with an estimated average price of $5.84. The stock is now traded at around $7.290000. The impact to a portfolio due to this purchase was 0.46%. The holding were 1,100,000 shares as of 2021-09-30.

Altium Capital Management LP added to a holding in Immatics NV by 39.01%. The purchase prices were between $11.58 and $15.46, with an estimated average price of $12.71. The stock is now traded at around $12.250000. The impact to a portfolio due to this purchase was 0.46%. The holding were 478,987 shares as of 2021-09-30.

Altium Capital Management LP sold out a holding in Chardan Healthcare Acquisition 2 Corp. The sale prices were between $8.41 and $10.15, with an estimated average price of $9.96.

Altium Capital Management LP sold out a holding in Palisade Bio Inc. The sale prices were between $2.35 and $3.93, with an estimated average price of $2.95.

Altium Capital Management LP sold out a holding in ESSA Pharma Inc. The sale prices were between $7.76 and $29.37, with an estimated average price of $15.99.

Altium Capital Management LP sold out a holding in electroCore Inc. The sale prices were between $0.93 and $1.18, with an estimated average price of $1.03.

Altium Capital Management LP sold out a holding in Sientra Inc. The sale prices were between $5.33 and $8.53, with an estimated average price of $6.84.

Altium Capital Management LP sold out a holding in BriaCell Therapeutics Corp. The sale prices were between $4.4 and $9.28, with an estimated average price of $6.12.